Browse drugs

…2.879)−3.542 (13.781)16.128 (6.086 to 26.170)0.003TPP effect (%)Benfotiamine (24)Placebo (27)12.975 (7.915)13.667 (7.063)4.217 (5.008)13.104…

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

…systemic palliative chemotherapy with NALIRIFOX, mFOLFIRINOX or Gem/NabP between January 2021 and July 2024. Key eligibility criteria re…

…ilar course in their T2DM trajectory compared with those not on metformin). For individuals with multiple COVID-19 tests, we excluded all…

…rom 0.88 to 0.92 in the full dataset, and from 0.93 to 0.95 for HRT prescriptions since 2016. These patterns were similar for all e…

…ever, these studies did not employ suitable active comparators. Metformin is often prescribed as first-line therapy in T2DM management, w…

…mens alone (PF vs GP) and (I–L) depict the oral regimens alone (capecitabine vs S-1); within each panel set the endpoints are, respectively,…

…ypically delivered 5 days a week over 7 weeks concurrently with cisplatin, a regimen established through multiple randomised trials, demo…

…, whereby researchers are investigating the use of subcutaneous semaglutide 2.4 mg/week for the treatment of adults with non-cirrhotic MASH…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…

…e age, duration of T2D, sex, BMI (<30, ≥30 and <35, ≥35 kg/m2), dulaglutide dose, and duration of dulaglutide treatment. The tirzepatide tr…

… outcome (10%), and incident CKD stages 3–4 (23%) compared with glipizide. However, glyburide was associated with significantly higher ri…